NovaBridge Biosciences Appoints New CEO, Announces Multiple Board and Executive Changes
NBP is trading near its 52-week low of $1.46 (10% above the low) on light trading volume (0.2× avg).
Summary
NovaBridge Biosciences announced a major leadership overhaul, appointing Dr. Srishti Gupta as its new CEO while the previous CEO, two board members, and the President (from his presidential role) depart.
Key Events · Executive and Board Changes · NBP
-
New CEO Appointed
Dr. Srishti Gupta, a former CEO of Idorsia Pharmaceuticals and McKinsey veteran, has been appointed Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026.
-
Previous CEO Resigns
Xi-Yong (Sean) Fu has resigned as Chief Executive Officer and Board member, effective June 30, 2026, and will support the company in an advisory capacity during the transition.
-
Multiple Board Directors Depart
Emmett T. Cunningham, Jr. and Sean Cao have also tendered their resignations as members of the Board of Directors, effective June 30, 2026. Dr. Cunningham will join the Scientific Advisory Board.
-
President Steps Down from Role
Mark Hagler, who was recently appointed President and Chief Commercial Officer, has resigned as President, effective July 1, 2026, but will continue to serve as Chief Commercial Officer.
Analysis · NBP · Life Sciences
This filing details a significant leadership restructuring at NovaBridge Biosciences. The appointment of Dr. Srishti Gupta, a seasoned biopharma executive, as the new CEO and board member is a major development. However, it coincides with the departure of the previous CEO, two board directors, and the President stepping down from his role (though remaining CCO). While the company states these resignations were not due to disagreements, such extensive changes at the top introduce a period of transition and potential strategic shifts, especially following recent positive clinical news.
At the time of this filing, NBP was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $189.2M. The 52-week trading range was $1.46 to $6.79. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.